El efecto protector renal de Metformina y Vildagliptina en pacientes con Síndrome Metabólico

This study focuses on understanding the relationship between different parts of metabolic syndrome and the occurrence of kidney injury. It also aims to explore the protective effects of two antidiabetic drugs, Metformin and Vildagliptin, on the kidneys. The study is particularly interested in figuring out if this protective action is linked to their blood sugar lowering properties or if there's another mechanism at play. This research is important as it could help improve treatment strategies for metabolic syndrome and slow down the progression of kidney damage in diabetic patients. Participants in this study will be administered either Metformin or Vildagliptin. The study will then evaluate the impact of these drugs on blood pressure, a key component of metabolic syndrome. Additionally, it will assess how these medications improve patients' conditions and reduce complications of metabolic syndrome. This will be done by measuring glucose levels in the blood and insulin levels in the plasma to calculate insulin resistance. The study also aims to understand if these drugs can slow down the worsening of metabolic syndrome.